Carcinotech provides comprehensive solid tumor research services to advance drug development and enhance personalized therapy decisions. At the heart of its offerings is the proprietary Carcino3D™ bioprinting technology, which creates assay-ready, 3D tumors derived from patient biopsies. This innovative, translational approach delivers a predictive in vitro model, generating critical insights into therapeutic efficacy, and treatment optimization.
Company Details
- Employees
- 16
- Founded
- -
- Address
- Roslin Innovation Centre, Easter Bush Campus,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- carcinotech.co.uk
- Keywords
- Cancer research, 3D bioprinting, Cancer microenvironment, drug testing, oncology, assay services, oncology pre-clinical services, solid tumours, solid tumors, tumour microenvironment, tumor microenvironment, early phase drug development, early drug discovery.
- HQ
- Edinburgh, Midlothian
Carcinotech Questions
Carcinotech's website is carcinotech.co.uk
Carcinotech's LinkedIn profile is https://uk.linkedin.com/company/carcinotech
Carcinotech has
16 employees.
View email and phone details for 16
employees at Carcinotech.
Carcinotech's industry is
Biotechnology Research
Carcinotech's top competitors are
Roukenbio,
Lateral Dx,
Kleboe Jardine Ltd,
Ingenza Ltd,
Cytomos,
Bioliberty,
Cytochroma,
Cellink,
Censo Biotechnologies (Axol Bioscience Ltd.),
Cumulus Oncology.
Carcinotech's categories are Biotechnology Research
Carcinotech's founding year is 2018
